2021 Q1 Form 10-Q Financial Statement

#000144736221000108 Filed on May 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $22.81M $17.42M
YoY Change 30.97% 99.82%
Cost Of Revenue $3.028M $2.391M
YoY Change 26.64% 49.62%
Gross Profit $19.79M $15.03M
YoY Change 31.66% 111.08%
Gross Profit Margin 86.73% 86.27%
Selling, General & Admin $18.16M $11.08M
YoY Change 63.94% 83.2%
% of Gross Profit 91.79% 73.72%
Research & Development $5.908M $2.913M
YoY Change 102.81% 108.97%
% of Gross Profit 29.86% 19.39%
Depreciation & Amortization $233.0K $91.00K
YoY Change 156.04% 18.18%
% of Gross Profit 1.18% 0.61%
Operating Expenses $24.07M $13.99M
YoY Change 72.03% 88.03%
Operating Profit -$4.284M $1.036M
YoY Change -513.51% -421.74%
Interest Expense $0.00 $764.0K
YoY Change -100.0% -25.39%
% of Operating Profit 73.75%
Other Income/Expense, Net $0.00
YoY Change -100.0%
Pretax Income -$4.280M $570.0K
YoY Change -850.88% -141.91%
Income Tax $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings -$4.280M $570.0K
YoY Change -850.88% -141.97%
Net Earnings / Revenue -18.76% 3.27%
Basic Earnings Per Share -$0.17 $0.03
Diluted Earnings Per Share -$0.17 $0.03
COMMON SHARES
Basic Shares Outstanding 24.91M shares 17.37M shares
Diluted Shares Outstanding 24.91M shares 18.73M shares

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $407.0M $98.70M
YoY Change 312.36% 509.26%
Cash & Equivalents $407.0M $98.65M
Short-Term Investments
Other Short-Term Assets $3.100M $2.100M
YoY Change 47.62% 200.0%
Inventory $2.310M $1.219M
Prepaid Expenses
Receivables $14.29M $14.60M
Other Receivables $0.00 $0.00
Total Short-Term Assets $426.7M $116.6M
YoY Change 266.08% 331.67%
LONG-TERM ASSETS
Property, Plant & Equipment $7.780M $2.733M
YoY Change 184.67% 60.76%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.761M $216.0K
YoY Change 715.28% -69.14%
Total Long-Term Assets $10.66M $3.705M
YoY Change 187.77% -7.38%
TOTAL ASSETS
Total Short-Term Assets $426.7M $116.6M
Total Long-Term Assets $10.66M $3.705M
Total Assets $437.3M $120.3M
YoY Change 263.66% 287.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.172M $1.934M
YoY Change 12.31% 20.88%
Accrued Expenses $7.200M $4.900M
YoY Change 46.94% 28.95%
Deferred Revenue $8.178M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $8.333M
YoY Change
Total Short-Term Liabilities $17.58M $15.26M
YoY Change 15.22% 69.51%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $17.01M
YoY Change -100.0% -27.91%
Other Long-Term Liabilities $1.200M $100.0K
YoY Change 1100.0% -91.67%
Total Long-Term Liabilities $1.200M $17.01M
YoY Change -92.95% -31.4%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.58M $15.26M
Total Long-Term Liabilities $1.200M $17.01M
Total Liabilities $18.75M $32.32M
YoY Change -42.01% -4.37%
SHAREHOLDERS EQUITY
Retained Earnings -$66.78M -$51.64M
YoY Change 29.31%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $418.6M $87.93M
YoY Change
Total Liabilities & Shareholders Equity $437.3M $120.3M
YoY Change 263.66% 287.93%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$4.280M $570.0K
YoY Change -850.88% -141.97%
Depreciation, Depletion And Amortization $233.0K $91.00K
YoY Change 156.04% 18.18%
Cash From Operating Activities -$3.631M -$251.0K
YoY Change 1346.61% -119.49%
INVESTING ACTIVITIES
Capital Expenditures $750.0K $500.0K
YoY Change 50.0% 104.92%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$750.0K -$500.0K
YoY Change 50.0% 104.92%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $1.510M $559.0K
YoY Change 170.13% -94.78%
NET CHANGE
Cash From Operating Activities -$3.631M -$251.0K
Cash From Investing Activities -$750.0K -$500.0K
Cash From Financing Activities $1.510M $559.0K
Net Change In Cash -$2.871M -$192.0K
YoY Change 1395.31% -101.63%
FREE CASH FLOW
Cash From Operating Activities -$3.631M -$251.0K
Capital Expenditures $750.0K $500.0K
Free Cash Flow -$4.381M -$751.0K
YoY Change 483.36% -171.93%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001447362
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity File Number
EntityFileNumber
001-38984
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
CASTLE BIOSCIENCES, INC.
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0701774
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
505 S. Friendswood Drive
CY2021Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 401
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Friendswood
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77546
CY2021Q1 dei City Area Code
CityAreaCode
866
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
788-9007
CY2021Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2021Q1 dei Trading Symbol
TradingSymbol
CSTL
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
25056411 shares
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
406981000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
409852000 USD
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
14292000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
12759000 USD
CY2021Q1 us-gaap Inventory Net
InventoryNet
2310000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
2217000 USD
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3087000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4766000 USD
CY2021Q1 us-gaap Assets Current
AssetsCurrent
426670000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
429594000 USD
CY2021Q1 us-gaap Accounts Receivable Net Noncurrent
AccountsReceivableNetNoncurrent
1121000 USD
CY2020Q4 us-gaap Accounts Receivable Net Noncurrent
AccountsReceivableNetNoncurrent
1096000 USD
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7780000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7102000 USD
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1761000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1536000 USD
CY2021Q1 us-gaap Assets
Assets
437332000 USD
CY2020Q4 us-gaap Assets
Assets
439328000 USD
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2172000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2098000 USD
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5208000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9108000 USD
CY2021Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8178000 USD
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
6615000 USD
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2020000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3055000 USD
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
17578000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
20876000 USD
CY2021Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
172000 USD
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1735000 USD
CY2021Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
995000 USD
CY2020Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1026000 USD
CY2021Q1 us-gaap Liabilities
Liabilities
18745000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
23637000 USD
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q1 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 USD
CY2020Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 USD
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25054513 shares
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25054513 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24812487 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24812487 shares
CY2021Q1 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
25000 USD
CY2020Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
25000 USD
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
485338000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
478162000 USD
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-66776000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-62496000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
418587000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
415691000 USD
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
437332000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
439328000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
22813000 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17418000 USD
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3028000 USD
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2391000 USD
CY2021Q1 us-gaap Gross Profit
GrossProfit
19785000 USD
CY2020Q1 us-gaap Gross Profit
GrossProfit
15027000 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5908000 USD
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2913000 USD
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
18161000 USD
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11078000 USD
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
24069000 USD
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
13991000 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4284000 USD
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
1036000 USD
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
4000 USD
CY2020Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
298000 USD
CY2021Q1 us-gaap Interest Expense
InterestExpense
0 USD
CY2020Q1 us-gaap Interest Expense
InterestExpense
764000 USD
CY2021Q1 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-4280000 USD
CY2020Q1 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
570000 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4280000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1577000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4280000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
570000 USD
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
570000 USD
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24912000 shares
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17372000 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24912000 shares
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18734000 shares
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
85113000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
71000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
603000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
570000 USD
CY2021Q1 us-gaap Accrued Bonuses Current And Noncurrent
AccruedBonusesCurrentAndNoncurrent
2664000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
87934000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
415691000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
4913000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
991000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1233000 USD
CY2021Q1 cstl Adjustments To Additional Paid In Capital Stock Issuance Costs Adjustments Increase
AdjustmentsToAdditionalPaidInCapitalStockIssuanceCostsAdjustmentsIncrease
39000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4280000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
418587000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4280000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
570000 USD
CY2021Q1 us-gaap Depreciation
Depreciation
233000 USD
CY2020Q1 us-gaap Depreciation
Depreciation
91000 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4913000 USD
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1577000 USD
CY2021Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
0 USD
CY2020Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
224000 USD
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
225000 USD
CY2020Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
77000 USD
CY2021Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-33000 USD
CY2020Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1558000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-161000 USD
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1679000 USD
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
129000 USD
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
93000 USD
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-19000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-40000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
56000 USD
CY2021Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-3899000 USD
CY2020Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-2645000 USD
CY2021Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-330000 USD
CY2020Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-96000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-500000 USD
CY2021Q1 cstl Increase Decreasein Deferred Lease Liability
IncreaseDecreaseinDeferredLeaseLiability
-64000 USD
CY2020Q1 cstl Increase Decreasein Deferred Lease Liability
IncreaseDecreaseinDeferredLeaseLiability
-2000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3631000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-251000 USD
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
750000 USD
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
500000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-750000 USD
CY2021Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
336000 USD
CY2020Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
991000 USD
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
71000 USD
CY2021Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
855000 USD
CY2020Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
488000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1510000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
559000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
98653000 USD
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
220000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2871000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-192000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
409852000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
98845000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
406981000 USD
CY2020Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
270000 USD
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates include revenue recognition, the valuation of stock-based compensation, assessing future tax exposure and the realization of deferred tax assets, the useful lives and recoverability of property and equipment, and contingent liabilities. We base these estimates on historical and anticipated results, trends, and various other assumptions that we believe are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions. We have considered the potential impact of the COVID-19 pandemic on our estimates and assumptions. The extent to which the COVID-19 pandemic may impact our estimates in future periods is uncertain and subject to change.
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 USD
CY2021Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 USD
CY2020Q4 us-gaap Accrued Bonuses Current And Noncurrent
AccruedBonusesCurrentAndNoncurrent
7175000 USD
CY2021Q1 cstl Contract With Customer Customer Payment Terms
ContractWithCustomerCustomerPaymentTerms
P30D
CY2021Q1 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
5335000 USD
CY2020Q1 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
3160000 USD
CY2020Q2 cstl Centers For Medicare And Medicaid Services Accelerated And Advanced Payment Program Payment Received
CentersForMedicareAndMedicaidServicesAcceleratedAndAdvancedPaymentProgramPaymentReceived
8300000 USD
CY2021Q1 cstl Revenue From Contract With Customer Revenue Not Yet Recognized Number Of Claims In Adjudication Process
RevenueFromContractWithCustomerRevenueNotYetRecognizedNumberOfClaimsInAdjudicationProcess
2698 claim
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-4280000 USD
CY2020Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
570000 USD
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24912000 shares
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17372000 shares
CY2021Q1 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2020Q1 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
27000 shares
CY2021Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2020Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1310000 shares
CY2021Q1 cstl Incremental Common Shares Attributableto Dilutive Effectof Shares Issued Under Employee Stock Purchase Plan
IncrementalCommonSharesAttributabletoDilutiveEffectofSharesIssuedUnderEmployeeStockPurchasePlan
0 shares
CY2020Q1 cstl Incremental Common Shares Attributableto Dilutive Effectof Shares Issued Under Employee Stock Purchase Plan
IncrementalCommonSharesAttributabletoDilutiveEffectofSharesIssuedUnderEmployeeStockPurchasePlan
25000 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24912000 shares
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18734000 shares
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3540000 shares
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
969000 shares
CY2021Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9667000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8756000 USD
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1887000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1654000 USD
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7780000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7102000 USD
CY2021Q1 us-gaap Depreciation
Depreciation
233000 USD
CY2020Q1 us-gaap Depreciation
Depreciation
91000 USD
CY2021Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1368000 USD
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1891000 USD
CY2021Q1 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
276000 USD
CY2020Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
276000 USD
CY2021Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
158000 USD
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
536000 USD
CY2021Q1 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
97000 USD
CY2020Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
151000 USD
CY2021Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
62000 USD
CY2020Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
62000 USD
CY2021Q1 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
59000 USD
CY2020Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
139000 USD
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2020000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3055000 USD
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3369502 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
28.11
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
53908 shares
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
75.44
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
170484 shares
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.67
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
74584 shares
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
24.69
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3178342 shares
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
30.20
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M21D
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
122017000 USD
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
836184 shares
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
13.48
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y6M14D
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
45970000 USD
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
53676 shares
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4913000 USD
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1577000 USD
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
55441000 USD
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y3M18D

Files In Submission

Name View Source Status
0001447362-21-000108-index-headers.html Edgar Link pending
0001447362-21-000108-index.html Edgar Link pending
0001447362-21-000108.txt Edgar Link pending
0001447362-21-000108-xbrl.zip Edgar Link pending
cstl-20210331.htm Edgar Link pending
cstl-20210331.xsd Edgar Link pending
cstl-20210331_cal.xml Edgar Link unprocessable
cstl-20210331_def.xml Edgar Link unprocessable
cstl-20210331_htm.xml Edgar Link completed
cstl-20210331_lab.xml Edgar Link unprocessable
cstl-20210331_pre.xml Edgar Link unprocessable
exhibit101-firstamendmentt.htm Edgar Link pending
exhibit102-employmentagree.htm Edgar Link pending
exhibit103-employmentagree.htm Edgar Link pending
exhibit104-nonxemployeedir.htm Edgar Link pending
exhibit311-q12021.htm Edgar Link pending
exhibit312-q12021.htm Edgar Link pending
exhibit321-q12021.htm Edgar Link pending
exhibit322-q12021.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending